You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Merck
AstraZeneca
Medtronic
Harvard Business School
McKinsey

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,376,496

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,376,496 protect, and when does it expire?

Patent 10,376,496 protects ZERBAXA and is included in one NDA.

This patent has six patent family members in three countries.

Summary for Patent: 10,376,496
Title:Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
Abstract: Disclosed are methods of administering cephalosporin/tazobactam to human patients with end stage renal disease undergoing hemodialysis and suffering from a complicated intra-abdominal infection or a complicated urinary tract infection.
Inventor(s): Krishna; Gopal (Stow, MA), Chandorkar; Gurudatt (Waltham, MA), Hershberger; Elham (Lexington, MA), Miller; Benjamin (Cambridge, MA), Xiao; Alan (Lexington, MA)
Assignee: Merck, Sharp & Dohme Corp. (Rahway, NJ)
Application Number:14/481,496
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 10,376,496

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;INTRAVENOUS 206829-001 Dec 19, 2014 RX Yes Yes   Start Trial   Start Trial TREATMENT OF COMPLICATED URINARY TRACT INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS   Start Trial
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;INTRAVENOUS 206829-001 Dec 19, 2014 RX Yes Yes   Start Trial   Start Trial TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,376,496

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014233637   Start Trial
Australia 2016202199   Start Trial
Australia 2017279686   Start Trial
Australia 2020202756   Start Trial
European Patent Office 3043797   Start Trial
World Intellectual Property Organization (WIPO) 2015035376   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Mallinckrodt
Dow
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.